Piribo: Peptides 2006: New Applications in Discovery, Manufacturing, and Therapeutics

To date, three types of molecules have been developed for the treatment of human diseases. These major classes of molecules are 1) small molecules, 2) antibodies, and 3) peptides. Currently, the majority of the therapeutic molecules developed and marketed are small molecules. However, with the recent development in several technologies in the areas of peptide synthesis, screening, stability, and modifications, peptides are now recognized as lead molecules for therapeutics.

This report contains a comprehensive analysis of peptide-based technologies, peptides for therapeutics, and their delivery mechanisms. In addition, it provides a thorough analysis of companies that have developed new peptides and related technologies.
Peptides 2006 analyzes the current peptide market. It features an analysis of therapeutic peptide products in multiple disease indications, as well as an up to date overview of key patent issues in this space. Numerous peptide therapeutic companies are profiled and details of their specialization, capabilities, and services are provided. The Report offers multiple experts’ opinion on current application and issues related to peptides. Results from an analysis of a proprietary survey conducted on current issues in peptides are a key component of this report as well.

“Peptides 2006: New Applications in Discovery, Manufacturing, and Therapeutics” is available in both hard copy and PDF format from Piribo. For more information go to: http://www.piribo.com/search/results.html?k=DMD071&x=5&y=9

Piribo Product Code: DMD071

About Piribo.
Piribo is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,500 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.